Bailey.Glen at 21:41, 4 December 2023

2023-12-04T21:41:40Z

← Older revision		Revision as of 16:41, 4 December 2023
Line 15:		Line 15:
	==Cancer Category/Type==		==Cancer Category/Type==

	* [[Mature T- and NK-cell Neoplasms]]		* [[HAEM4:Mature T- and NK-cell Neoplasms]]

	==Cancer Sub-Classification / Subtype==		==Cancer Sub-Classification / Subtype==

	* [[~~Anaplastic Large Cell Lymphoma,~~ ALK-~~Negative~~]]		* [[HAEM5:ALK-negative anaplastic large cell lymphoma]]

	==Definition / Description of Disease==		==Definition / Description of Disease==
Line 129:		Line 129:
	==Links==		==Links==

	* [[~~Anaplastic Large Cell Lymphoma,~~ ALK-~~Negative~~]]		* [[HAEM5:ALK-negative anaplastic large cell lymphoma]]
	* [[~~Anaplastic Large Cell Lymphoma,~~ ALK-~~Positive~~]]		* [[HAEM5:ALK-positive anaplastic large cell lymphoma]]

	==References==		==References==

Bailey.Glen at 18:57, 3 November 2023

2023-11-03T18:57:16Z

@@ Line 1: / Line 1: @@
 {{Under Construction}}
 ==Primary Author(s)*==
@@ Line 133: / Line 138: @@
 ==Notes==
 <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.

Bailey.Glen: Created page with "{{Under Construction}} ==Primary Author(s)== Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center TOC ==Cancer Category/Type== Mature T-..."

2023-11-03T18:23:40Z

Created page with "{{Under Construction}} ==Primary Author(s)*== Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center __TOC__ ==Cancer Category/Type== * Mature T-..."

New page

{{Under Construction}}
==Primary Author(s)*==

Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD

Cedars-Sinai Medical Center

__TOC__

==Cancer Category/Type==

* [[Mature T- and NK-cell Neoplasms]]

==Cancer Sub-Classification / Subtype==

* [[Anaplastic Large Cell Lymphoma, ALK-Negative]]

==Definition / Description of Disease==

*Provisional entity in WHO 2016 classification
*Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell lymphoproliferative disorder that occurs in patients with breast implants.
*Belongs to the so-called triple negative category of systemic anaplastic large cell lymphomas (sALCL)<ref name=":1">{{Cite journal|last=N|first=Oishi|last2=Gs|first2=Brody|last3=Rp|first3=Ketterling|last4=Ds|first4=Viswanatha|last5=R|first5=He|last6=S|first6=Dasari|last7=M|first7=Mai|last8=Hk|first8=Benson|last9=Ca|first9=Sattler|date=2018|title=Genetic subtyping of breast implant-associated anaplastic large cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/29921615/|language=en|doi=10.1182/blood-2017-12-821868|pmc=PMC6073323|pmid=29921615}}</ref>

==Synonyms / Terminology==

* Seroma-associated anaplastic large cell lymphoma

==Epidemiology / Prevalence==

*Rare (fewer than 1 in 100,000 with implants)<ref name=":2">{{Cite journal|last=Gs|first=Brody|last2=D|first2=Deapen|last3=Cr|first3=Taylor|last4=L|first4=Pinter-Brown|last5=Sr|first5=House-Lightner|last6=Js|first6=Andersen|last7=G|first7=Carlson|last8=Mg|first8=Lechner|last9=Al|first9=Epstein|date=2015|title=Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases|url=https://pubmed.ncbi.nlm.nih.gov/25490535/|language=en|pmid=25490535}}</ref>
*No association with type of implant (silicone vs. saline, textured vs. smooth)<ref name=":2" />
*Median time to lymphoma diagnosis after implant is 8-9 years<ref name=":2" />
*Mean age 50<ref name=":2" />

==Clinical Features==

*Pain, swelling around implant<ref name=":3">{{Cite journal|last=D|first=Lazzeri|last2=T|first2=Agostini|last3=G|first3=Bocci|last4=G|first4=Giannotti|last5=G|first5=Fanelli|last6=Ag|first6=Naccarato|last7=R|first7=Danesi|last8=M|first8=Tuccori|last9=M|first9=Pantaloni|date=2011|title=ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity|url=https://pubmed.ncbi.nlm.nih.gov/21729665/|language=en|pmid=21729665}}</ref>
*Peri-implant effusion most common (approximately 80% cases)<ref name=":3" />
*Axillary lymphadenopathy<ref name=":3" />
*Extracapsular extension to form a solid mass of tumor cells possible<ref name=":3" />

==Sites of Involvement==

*Peri-implant (Stage I)
*Extracapsular dissemination not uncommon

==Morphologic Features==

*Large, pleomorphic<ref name=":0">{{Cite journal|last=Rn|first=Miranda|last2=Tn|first2=Aladily|last3=Hm|first3=Prince|last4=R|first4=Kanagal-Shamanna|last5=D|first5=de Jong|last6=Le|first6=Fayad|last7=Mb|first7=Amin|last8=N|first8=Haideri|last9=G|first9=Bhagat|date=2014|title=Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients|url=https://pubmed.ncbi.nlm.nih.gov/24323027/|language=en|doi=10.1200/JCO.2013.52.7911|pmc=PMC4062709|pmid=24323027}}</ref><ref name=":4">{{Cite journal|last=Sh|first=Swerdlow|last2=E|first2=Campo|last3=Sa|first3=Pileri|last4=Nl|first4=Harris|last5=H|first5=Stein|last6=R|first6=Siebert|last7=R|first7=Advani|last8=M|first8=Ghielmini|last9=Ga|first9=Salles|date=2016|title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms|url=https://pubmed.ncbi.nlm.nih.gov/26980727/|language=en|doi=10.1182/blood-2016-01-643569|pmc=PMC4874220|pmid=26980727}}</ref>
*Hallmark cells<ref name=":0" /><ref name=":4" />

==Immunophenotype==

{| class="wikitable sortable"
|-
!Finding<ref name=":1" /><ref>{{Cite journal|last=Ae|first=Quesada|last2=Lj|first2=Medeiros|last3=Mw|first3=Clemens|last4=Mc|first4=Ferrufino-Schmidt|last5=S|first5=Pina-Oviedo|last6=Rn|first6=Miranda|date=2019|title=Breast implant-associated anaplastic large cell lymphoma: a review|url=https://pubmed.ncbi.nlm.nih.gov/30206414/|language=en|pmid=30206414}}</ref>!!Marker
|-
|Positive (universal)||CD30
|-
|Positive (frequent)
|Varying pan T-cell antigen expression (CD3, CD2, CD5, CD7, CD4, CD8), MUM1
|-
|Negative (universal)||ALK
|}

==Chromosomal Rearrangements (Gene Fusions)==

*Not described

==Characteristic Chromosomal Aberrations / Patterns==

*N/A

==Genomic Gain/Loss/LOH==

*N/A

==Gene Mutations (SNV/INDEL)==

*JAK1 and STAT3 mutation (variable pattern leads to activation)<ref>{{Cite journal|last=P|first=Blombery|last2=Er|first2=Thompson|last3=K|first3=Jones|last4=Gm|first4=Arnau|last5=S|first5=Lade|last6=Jf|first6=Markham|last7=J|first7=Li|last8=A|first8=Deva|last9=Rw|first9=Johnstone|date=2016|title=Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/27198716/|language=en|doi=10.3324/haematol.2016.146118|pmc=PMC5060038|pmid=27198716}}</ref><ref>{{Cite journal|last=A|first=Di Napoli|last2=P|first2=Jain|last3=E|first3=Duranti|last4=E|first4=Margolskee|last5=W|first5=Arancio|last6=F|first6=Facchetti|last7=B|first7=Alobeid|last8=F|first8=Santanelli di Pompeo|last9=M|first9=Mansukhani|date=2018|title=Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A|url=https://pubmed.ncbi.nlm.nih.gov/27859003/|language=en|pmid=27859003}}</ref>

'''PUT IN THE TABLE FROM THE TEMPLATE, SO THE FREQUENCY OF THESE MUTATIONS AND THEIR SIGNIFICANCE CAN BE ENTERED.'''

==Epigenomics (Methylation)==

*Not described

==Genes and Main Pathways Involved==

*JAK/STAT activation<ref name=":5">{{Cite journal|last=Kim|first=Won Seog|date=2017-11-30|title=Faculty Opinions recommendation of Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.|url=http://dx.doi.org/10.3410/f.725957551.793539732}}</ref><ref name=":1" />
*MYC/TP53 dysregulation<ref name=":5" /><ref name=":1" />

==Diagnostic Testing Methods==

*Morphologic and immunohistochemical evaluation of aspirated seroma/effusion fluid and/or capsulectomy specimen
*Exclude secondary involvement by systemic ALK(-) ALCL

==Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)<ref>{{Cite journal|last=Mw|first=Clemens|last2=Ed|first2=Jacobsen|last3=Sm|first3=Horwitz|date=2019|title=2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)|url=https://pubmed.ncbi.nlm.nih.gov/30715173/|language=en|pmid=30715173}}</ref><ref>{{Cite journal|last=Mc|first=Ferrufino-Schmidt|last2=Lj|first2=Medeiros|last3=H|first3=Liu|last4=Mw|first4=Clemens|last5=Kk|first5=Hunt|last6=C|first6=Laurent|last7=J|first7=Lofts|last8=Mb|first8=Amin|last9=S|first9=Ming Chai|date=2018|title=Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/29194092/|language=en|pmid=29194092}}</ref><ref name=":0" />==
'''THIS SECTION IS REALLY FOR THE DIAGNOSTIC, PROGNOSTIC, AND THERAPEUTIC SIGNIFICANCE OF THE MOLECULAR CHANGES FOUND IN THIS ENTITY. YOU CAN KEEP THE WORK YOU HAVE DONE BUT PERHAPS MOVE IT TO "OTHER INFORMATION" SECTION?'''

*
*'''Diagnosis'''
**Clinical history (skin rash, ulcer or skin mass > 1 year after breast implant),
**Ultrasound or MRI
**Fine needle aspiration or tissue biopsy for morphologic and immunophenotypic analysis
**For disseminated disease, clinical history of breast implants and negative DUSP22 and TP63 FISH studies strongly supports diagnosis and makes other sALCL's unlikely
*'''Prognosis'''
**Excellent prognosis (median survival over 12 years)
**If extracapsular extension present, systemic therapy may be indicated
*'''Therapeutic Implications'''
**Focal disease: capsulectomy and implant removal followed by radiotherapy or watchful waiting
**Disseminated disease: systemic therapy
**Anthracyclin-based chemotherapy with brentuximab-vedotin superior to chemotherapy alone<ref>{{Cite journal|last=L|first=Johnson|last2=Jm|first2=O'Donoghue|last3=N|first3=McLean|last4=P|first4=Turton|last5=Aa|first5=Khan|last6=Sd|first6=Turner|last7=A|first7=Lennard|last8=N|first8=Collis|last9=M|first9=Butterworth|date=2017|title=Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent|url=https://pubmed.ncbi.nlm.nih.gov/28596034/|language=en|pmid=28596034}}</ref>

==Familial Forms==

*None

==Other Information==

* None

==Links==

* [[Anaplastic Large Cell Lymphoma, ALK-Negative]]
* [[Anaplastic Large Cell Lymphoma, ALK-Positive]]

==References==
(use "Cite" icon at top of page)
<references />

==Notes==
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.

HAEM4:Breast Implant-Associated Anaplastic Large Cell Lymphoma - Revision history

Bailey.Glen at 21:41, 4 December 2023

Bailey.Glen at 18:57, 3 November 2023

Bailey.Glen: Created page with "{{Under Construction}} ==Primary Author(s)*== Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center __TOC__ ==Cancer Category/Type== * Mature T-..."

Bailey.Glen: Created page with "{{Under Construction}} ==Primary Author(s)== Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center TOC ==Cancer Category/Type== Mature T-..."